I-Mab's Givastomig: A Potential Game Changer for Stomach Cancer Treatment
I-Mab's givastomig is a unique immune-boosting drug for stomach cancer, expected to outperform competitors, according to Leerink.
/ 1680 items
#XY↓
U.S. FDA Approves Jazz's Combination Therapy for Lung Cancer
The FDA approved the Zepzelca/Tecentriq drug combo as a maintenance treatment for advanced small cell lung cancer.
Gene Therapy Showdown: Taysha's Speed vs. Neurogene's Durability
A look at why analysts are favoring Neurogene over Taysha in the race for gene therapy approvals, focusing on study design, FDA alignment, and long-term patient outcomes.
Humana Affirms Guidance Despite Medicare Rating Flap
Humana’s 2026 Medicare Advantage quality ratings were accidentally released early, but the company affirmed its financial outlook, boosting investor confidence and setting the stage for major 2027 improvements.
Context Therapeutics: A Promising Cancer Drug Developer
A hidden cancer company, Context, got a top rating. Its ovarian cancer drug, CTIM-76, has key data coming in 2026.
Why Ultragenyx Stock Might Be Ready to Climb
JPMorgan is optimistic about Ultragenyx's drug setrusumab (UX143) and expects big gains ahead of key study updates.